Preclinical evidence for the use of PD-L1 inhibitors suggests that chordoma cells express PD-L1, expression of which is further inducible by interferon gamma, and that chordoma CSCs are sensitive to PD-L1 inhibitor-mediated ADCC (15, 20). This evidence concerns the gene IFNG and chordoma.